HealthcareServices

Global Chikungunya Market Size Projected to Reach $0.92 Billion During the Forecast Period

November 27, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Does The Market Size Of The Chikungunya Industry Compare Between 2025 And 2029?

The chikungunya market has demonstrated strong expansion in recent years. Its value is projected to rise from $0.59 billion in 2024 to $0.65 billion in 2025, showing a compound annual growth rate (CAGR) of 9.4%. This historical growth can be ascribed to several factors, including increasing per capita healthcare expenditures, the growing occurrence of emerging and re-emerging infectious diseases, rising personal disposable income, climate change, and heightened awareness about mosquito-borne illnesses.

The chikungunya market is projected to experience robust expansion over the coming years. Its valuation is set to reach $0.92 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 9.2%. This anticipated growth during the forecast period is driven by several factors, including an international surge in clinical trials, a demographic shift towards an older population, an escalating demand for immunization, a rise in both governmental and non-governmental initiatives, augmented government investments, and supportive policies. Key developments expected during this timeframe encompass biotechnological advancements in vaccine creation, emerging vaccine prospects, the application of CRISPR and AI for novel solutions, strategic alliances between pharmaceutical companies, and the incorporation of telemedicine services.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21137&type=smp

What Are The Main Drivers Boosting The Chikungunya Industry’s Expansion?

The increasing prevalence of mosquito-borne diseases is projected to drive the expansion of the chikungunya market going forward. Such diseases, including chikungunya, dengue, and zika virus, are transmitted to humans by infected aedes mosquitoes and present significant public health challenges globally. The worldwide rise in the incidence of mosquito-borne diseases is attributed to factors like climate change, urbanization, deforestation, accumulation of stagnant water, insufficient vector control measures, heightened global travel, and insecticide resistance. Chikungunya treatment assists mosquito-borne disease patients by easing symptoms such as fever, joint pain, and inflammation, thereby improving overall comfort and mobility, lowering the risk of complications, and fostering recovery through hydration, pain management, and supportive care. For instance, in December 2024, according to the UK Health Security Agency, a UK-based government agency, dengue cases among returning travelers in England, Wales, and Northern Ireland escalated to 473 between January and June 2024, reflecting a 201% increase when compared to the 157 cases documented during the same period in 2023. Therefore, the escalating global incidence of mosquito-borne diseases is a key factor propelling the growth of the chikungunya market.

What Are The Different Segment Classifications Within The Chikungunya Market?

The chikungunyamarket covered in this report is segmented –

1) By Type: Antiviral Drugs; Herbal And Complementary Treatments; Supportive Care; Vaccines

2) By Product Form: Liquid Form; Powder; Solid Form

3) By Disease Stage: Acute; Chronic; Post-Infection

4) By Sales Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies; Supermarkets

5) By End User: Caregivers; Healthcare Professionals; Patients

Subsegments:

1) By Antiviral Drugs: Nucleoside Analogues; Protease Inhibitors

2) By Herbal And Complementary Treatments: Ayurvedic Remedies; Homeopathic Treatments; Traditional Chinese Medicine

3) By Supportive Care: Pain Relievers (NSAIDs, Acetaminophen); Fluid Therapy; Physiotherapy

4) By Vaccines: Live-Attenuated Vaccines; Inactivated Vaccines; mRNA-Based Vaccines

What Trends Are Expected To Drive The Chikungunya Market?

Companies significantly involved in the chikungunya market are prioritizing the development of innovative vaccines aimed at strengthening immunity, preventing widespread disease, and addressing the escalating worldwide health burden associated with chikungunya virus infections. A live attenuated chikungunya vaccine is designed to employ a weakened version of the chikungunya virus to elicit an immune response without causing the illness, thereby providing lasting defense. For instance, in November 2023, Valneva SE, a biotechnology company based in France, announced that IXCHIQ, a live attenuated chikungunya vaccine, received approval from the Food and Drug Administration (FDA), a U.S. government agency. This approval was granted under an accelerated process, relying on anti-CHIKV neutralizing antibody titers, with continued endorsement dependent on verifying clinical benefit through confirmatory research. Valneva also received a Priority Review Voucher (PRV) from the FDA, which the company intends to commercialize to assist in funding its research and development programs. Ixchiq is administered as a single-dose intramuscular injection and contains a live, weakened strain of the chikungunya virus, which could potentially cause symptoms in recipients similar to those of chikungunya disease.

Which Major Industry Participants Are Leading The Chikungunya Market Growth?

Major companies operating in the chikungunya market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Quest Diagnostics Incorporated, Eurofins Scientific SE, Grifols Diagnostic Solutions Inc., bioMérieux SA, Bio-Rad Laboratories Inc., DiaSorin S.p.A., Euroimmun AG, Evotec SE, Valneva SE, ELITechGroup S.A.S., Vaxart Inc., BioPerfectus Biotechnology Co. Ltd., CTK Biotech Inc., Creative Diagnostics Inc., Inovio Pharmaceuticals Inc., Biotrol Laboratories Pvt. Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/chikungunya-global-market-report

Which Global Regions Are Influencing The Competitive Landscape Of The Chikungunya Market?

North America was the largest region in the chikungunya market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chikungunya market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Chikungunya Market Report:

https://www.thebusinessresearchcompany.com/customise?id=21137&type=smp

Browse Through More Reports Similar to the Global Chikungunya Market 2025, By The Business Research Company

Respiratory Disease Testing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/respiratory-disease-testing-global-market-report

Respiratory Disease Vaccine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/respiratory-disease-vaccine-global-market-report

Artificial Intelligence Ai In Respiratory Diseases Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-in-respiratory-diseases-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795